A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 31/52 (2006.01)
Patent
CA 2094154
2094154 9207585 PCTABS00013 A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy or prophylaxis of disorders associated with undesirably high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (known as Pentoxifylline or Trental) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanised recombinant antibody or fragment. The ratio of xanthine derivative to anti-TNF antibody component used may be in the range between 450:1 and 1:10 and doses of anti-TNF component in the range 0.001-30mg/kg/day and doses of xanthine derivative in the range 0.5 to 100mg/kg/day may be administered during treatment of human or animal subjects. It has been found that when an anti-TNF antibody and a xanthine derivative are used together in some experimental models of septic shock, a surprising combination effect is observed.
Anagnostopulos Hiristo
Bodmer Mark William
Gebert Ulrich
Hanel Heinz
Higgs Gerald Anthony
Celltech Therapeutics Limited
Hoechst Aktiengesellschaft
Kirby Eades Gale Baker
LandOfFree
Use of antibodies to tnf or fragments derived thereof and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antibodies to tnf or fragments derived thereof and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antibodies to tnf or fragments derived thereof and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1577749